Kadmon Investors and Media

Investors

Press Releases

Press Releases

FDA Grants Orphan Drug Designation to Kadmon's Belumosudil for the Treatment of Systemic Sclerosis

NEW YORK, NY / ACCESSWIRE / September 8, 2020   /   Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to belumosudil (KD025), the Company's Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment... Read More

Kadmon to Present at Upcoming Investor Conferences

NEW YORK, NY / ACCESSWIRE / September 2, 2020   /   Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal , M.D., President and Chief Executive Officer, will present at the following virtual investor conferences: H.C. Wainwright 22 nd Annual Global Investment Conference   Date:... Read More

Kadmon Announces Appointment of Nancy Miller-Rich to Board of Directors

NEW YORK, NY / ACCESSWIRE / August 13, 2020   /   Kadmon Holdings, Inc. (NYSE:KDMN) today announced the appointment of Nancy Miller-Rich to its Board of Directors. "Nancy possesses an extensive, decades-long track record of business development and commercialization success in varying roles across... Read More

Kadmon Provides Business Update and Reports Second Quarter 2020 Financial Results

NEW YORK, NY / ACCESSWIRE / August 6, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2020. "Following positive topline results from the primary analysis of the ROCKstar pivotal trial of belumosudil... Read More

Kadmon Doses First Patient in Phase 1 Clinical Trial of KD033, an Anti-PD-L1/IL-15 Fusion Protein, in Adults with Metastatic or Locally Advanced Solid Tumors

NEW YORK, NY / ACCESSWIRE / June 23, 2020 /   Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating KD033, an anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors.... Read More

Kadmon to Present at the Raymond James 2020 Virtual Human Health Innovation Conference

NEW YORK, NY / ACCESSWIRE / June 11, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal , M.D., President and Chief Executive Officer, will present at the Raymond James 2020 Virtual Human Health Innovation Conference on Thursday, June 18, 2020 at 1:00 p.m. ET .... Read More

Kadmon Raises $50 Million in Gross Proceeds Through Its at-the-Market Facility

NEW YORK, NY / ACCESSWIRE / June 5, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that it has raised gross proceeds of $50.0 million through its At-The-Market (ATM) facility, including participation based on interest received from existing shareholders and new healthcare specialist... Read More

Kadmon to Present at the Jefferies 2020 Virtual Global Healthcare Conference

NEW YORK, NY / ACCESSWIRE / May 27, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal , M.D., President and Chief Executive Officer, will present at the Jefferies 2020 Virtual Global Healthcare Conference on Thursday, June 4, 2020 at 4:00 p.m. ET .... Read More

Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease

ORRs of 73% and 74% with Belumosudil (KD025) 200 mg QD and 200 mg BID, Respectively Kadmon Participating in FDA's Real-Time Oncology Review Pilot Program Conference Call Today at 8:30 a.m. Eastern Time NEW YORK, NY / ACCESSWIRE / May 21, 2020 / Kadmon Holdings, Inc.... Read More

Kadmon Provides Business Update and Reports First Quarter 2020 Financial Results

NEW YORK, NY / ACCESSWIRE / May 7, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2020. "We made encouraging progress this past quarter, having completed our pre-NDA meeting with the FDA.... Read More
Displaying 1 - 10 of 15